Diplomat Pharmacy (DPLO) Misses Q3 EPS by $2.17, Revenues Beat; Lowers FY19 EPS Guidance Below Consensus, Raises FY19 Revenue Views Above Consensus
Tweet Send to a Friend
Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of ($2.35), $2.17 worse than the analyst estimate of ($0.18). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
